This first-in-class monoclonal antibody is use to reduce frequency in vast-occlusive episodes and is currently being used under a managed access programme (MAA).

This novel drug is indicated for the treatment of haemolytic anaemia in adult and paediatric patients with Sickle Cell Disease.